Sydnexis Appoints Perry J. Sternberg as Chief Executive Officer

Sydnexis, of Del Mar, California, announced July 16 that Perry J. Sternberg had been appointed chief executive officer and as a member of the board of directors.

He will join the company on Aug. 5, Sydnexis said.

Sydnexis is developing SYD-101, an atropine formulation to slow the progression of pediatric myopia. The Phase III STAR study is investigating two dosage strengths of SYD-101 in more than 850 children ages 3 to 14. 

Sydnexis said Perry had overseen more than 20 product launches across a wide range of therapeutic areas and markets. His 15-year tenure in eye care includes stints at Novartis, Bausch + Lomb, and Shire. He helped lead the successful launch and subsequent sale of the dry eye treatment Xiidra.